SI
ICPT

Sofinnova Investments’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Sofinnova Investments’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100,000
Closed -$1.63M – 71
2022
Q1 		$1.63M Sell
100,000
-50,400
-34% -$789K 0.12% 51
2021
Q4 		$2.45M Sell
150,400
-39,600
-21% -$668K 0.14% 61
2021
Q3 		$2.82M Buy
+190,000
New +$3.04M 0.17% 62

Other funds holding ICPT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Sofinnova Investments's ICPT Position: Q2 2019 in Review

Sofinnova Investments sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2019, closing a stake of 44,918 shares — an estimated $5.02M sold.

Sofinnova Investments first reported a position in ICPT in Q2 2018 and held it in 3 quarters. The position peaked at $8.96M in Q2 2018. 196 funds tracked by Wall St. Rank hold ICPT as of Q2 2019.

  • Sofinnova Investments reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Sofinnova Investments sold 44,918 Intercept Pharmaceuticals, Inc. shares in Q2 2019, an estimated $5.02M.
  • Sofinnova Investments first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2018 and held it in 3 quarters.
  • Sofinnova Investments's Intercept Pharmaceuticals, Inc. position peaked at $8.96M in Q2 2018.
  • 196 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2019.

Based on Sofinnova Investments's 13F filing for Q2 2019, filed 13 Aug 2019.